```html

Exophytic Cervical Cancer – A Complete Patient Guide

Overview

Exophytic cervical cancer is a type of invasive cervical carcinoma that grows outward from the cervical surface, forming a “bulging” or “polyp‑like” mass that can be visible on a pelvic exam. The term “exophytic” simply describes the growth pattern; it does not denote a separate disease entity. Most exophytic lesions are squamous cell carcinomas, the most common histology of cervical cancer, but adenocarcinomas can also present this way.

Who it affects: Cervical cancer primarily affects women of reproductive age, with the highest incidence between 35 and 55 years old. In the United States, about 13,000 new cases are diagnosed each year, and roughly 5‑10 % of these present as exophytic masses on initial examination. Worldwide, cervical cancer is the fourth most common cancer in women, with an estimated 604,000 new cases and 342,000 deaths in 2020 (WHO). Rates are highest in low‑ and middle‑income countries where screening programs are limited.

Because exophytic tumors are often visible, they may be detected earlier than flat (in‑situ) lesions, but they can also bleed or cause discomfort that prompts earlier medical attention.

Symptoms

Symptoms vary with tumor size, location, and stage. Many women are asymptomatic in the early phases, which underscores the importance of routine screening.

Common presenting signs

• Unusual vaginal bleeding – spotting between periods, post‑coital bleeding, or bleeding after menopause.
• Vaginal discharge – watery, mucous, or foul‑smelling discharge that may be continuous or intermittent.
• Pain – pelvic or lower‑back pain that may be dull or sharp, especially during intercourse (dyspareunia).
• Visible mass – on speculum examination a protruding growth may be seen; some women notice a “polyp” that protrudes from the cervix.

Less common but important symptoms

• Urinary frequency, urgency, or blood in the urine (if tumor invades the bladder).
• Constipation or rectal bleeding (if tumor extends toward the rectum).
• Weight loss, fatigue, or generalized malaise (often sign of advanced disease).
• Fever or night sweats (rare, usually with infection secondary to tumor necrosis).

Any unexplained vaginal bleeding or discharge after age 30 should prompt a medical evaluation, even if the symptom seems mild.

Causes and Risk Factors

Exophytic cervical cancer shares the same etiologic factors as other cervical cancers.

Human papillomavirus (HPV) infection

The single most important cause. Persistent infection with high‑risk HPV types—most commonly 16 and 18—leads to cellular changes that can progress to cancer over years. According to the CDC, about 70 % of cervical cancers are linked to HPV 16, and another 10 % to HPV 18.

Other risk factors

• Age – Incidence rises after age 30, peaks in the mid‑40s.
• Smoking – Tobacco carcinogens concentrate in cervical mucus and double the risk.
• Immunosuppression – HIV infection, organ‑transplant recipients, or long‑term corticosteroid use reduce clearance of HPV.
• Multiple sexual partners – Increases likelihood of acquiring high‑risk HPV.
• Early age at first intercourse – Associated with longer exposure to HPV.
• Long‑term use of oral contraceptives – >5 years of use slightly raises risk.
• Socioeconomic factors – Limited access to screening, vaccination, and health education.

Why exophytic?

When a cancerous lesion grows rapidly, the proliferating cells push outward, forming a polypoid mass. This pattern is more common in tumors with a robust blood supply and in patients whose immune response does not keep the lesion in a flat, in‑situ state.

Diagnosis

Early detection relies on routine screening, followed by targeted diagnostic tests when an abnormality is found.

Screening tools

• Pap smear (Pap test) – Cytology to identify abnormal cells. Recommended every 3 years for women 21‑29, and every 5 years (Pap + HPV) for women 30‑65 (American Cancer Society).
• HPV DNA testing – Detects high‑risk viral types. Often combined with Pap in “co‑testing”.

Diagnostic work‑up after an abnormal screen

1. Colposcopy – Magnified visual examination of the cervix with application of acetic acid. An exophytic lesion is easily seen as a raised, vascular mass.
2. Directed biopsy – Small tissue sample taken from the lesion for histopathology; confirms invasive carcinoma and determines grade.
3. Endocervical curettage (ECC) – Scrapes cells from the uterine canal to evaluate for hidden disease.
4. Imaging for staging:
   • Pelvic MRI – Provides detailed soft‑tissue assessment of tumor size, depth of stromal invasion, and involvement of adjacent structures.
   • CT scan – Evaluates lymph node enlargement and distant spread.
   • PET‑CT – Detects metabolically active metastatic disease.
5. Blood tests – Complete blood count, renal/hepatic panels (baseline before chemotherapy), and, in some cases, serum tumor markers (e.g., SCC‑Ag) for monitoring.

Staging

The FIGO (International Federation of Gynecology and Obstetrics) system is used worldwide. Exophytic tumors are classified the same as other cervical cancers based on size (T), lymph node status (N), and distant metastasis (M). Accurate staging guides treatment decisions.

Treatment Options

Treatment is individualized according to stage, tumor size, patient age, desire for fertility preservation, and overall health.

Early‑stage disease (FIGO IA‑IB1, tumor ≤2 cm)

• Conization (cold‑knife or loop electrosurgical excision procedure – LEEP) – Removes the lesion with a margin of healthy tissue; may be curative for microscopic disease.
• Radical hysterectomy – Removal of the uterus, cervix, upper vagina, and parametrial tissue; considered the gold standard for stage IB2‑IIA.
• Fertility‑preserving options – For selected women <45 years who wish to retain fertility, a radical trachelectomy (removal of the cervix while preserving the uterine body) may be performed.

Locally advanced disease (FIGO IIB‑IVA)

• Cisplatin‑based chemoradiation – Weekly intravenous cisplatin (40 mg/m²) combined with external beam radiation therapy (EBRT) followed by intracavitary brachytherapy. This combined approach improves 5‑year survival to 60‑70 % (NCI).
• Extended-field radiation – If para‑aortic lymph nodes are involved.

Metastatic or recurrent disease (FIGO IVB)

• Systemic chemotherapy – Cisplatin plus paclitaxel, or carboplatin + paclitaxel, often given every 3 weeks.
• Immunotherapy – Pembrolizumab (PD‑1 inhibitor) is FDA‑approved for PD‑L1‑positive, recurrent or metastatic cervical cancer (KEYNOTE‑158 trial).
• Targeted therapy – Anti‑angiogenic agent bevacizumab combined with chemotherapy improves overall survival (GOG‑240 trial).

Supportive and adjunctive measures

• Analgesics for pain control (acetaminophen, NSAIDs, or opioids as needed).
• Antiemetics for chemotherapy‑induced nausea (ondansetron, dexamethasone).
• Blood transfusion or iron supplementation for anemia caused by chronic bleeding.
• Lymphedema education after pelvic radiation or lymph node dissection.

Lifestyle considerations during treatment

• Stop smoking – improves treatment response and wound healing.
• Maintain adequate nutrition – high‑protein diet supports tissue repair.
• Stay hydrated, especially during radiation.

Living with Exophytic Cervical Cancer

Managing day‑to‑day life involves physical, emotional, and practical aspects.

Physical health

• Pelvic floor exercises – Kegels can reduce urinary symptoms after radiation.
• Skin care – Gentle cleansing of the vagina; avoid scented products that can irritate post‑radiation tissue.
• Activity – Light walking promotes circulation; avoid heavy lifting for 4–6 weeks after surgery.

Emotional wellbeing

• Seek counseling or join support groups (e.g., American Cancer Society’s Cervical Cancer Support Community).
• Practice stress‑reduction techniques such as mindfulness, yoga, or deep‑breathing.

Follow‑up care

After primary treatment, most guidelines recommend:

• Pelvic exam and Pap test every 3–6 months for the first 2 years.
• Imaging (CT or MRI) if symptoms suggest recurrence.
• Annual HPV testing may be considered, especially after treatment for high‑risk disease.

Fertility and sexual health

• If fertility was preserved, consult a reproductive specialist about timing of conception.
• Lubricants and vaginal moisturizers can alleviate dryness after radiation.
• Open communication with partners and healthcare providers about sexual concerns is essential.

Prevention

Most cases are preventable through primary and secondary measures.

Primary prevention

• HPV vaccination – The 9‑valent vaccine (Gardasil 9) protects against HPV 16, 18 and five other oncogenic types. CDC recommends routine vaccination at ages 11‑12, with catch‑up through age 26 (and shared decision‑making up to age 45).
• Safe sexual practices – Consistent condom use and limiting the number of sexual partners reduce HPV exposure.
• Smoking cessation – Lowers the synergistic risk of HPV‑related cancer.

Secondary prevention (screening)

• Regular Pap testing and co‑testing with HPV according to age‑specific guidelines.
• Prompt follow‑up of any abnormal results (ASC‑US, LSIL, HSIL).

General health maintenance

• Maintain a healthy weight and balanced diet rich in fruits, vegetables, and whole grains (may aid immune surveillance).
• Routine gynecologic care – annual pelvic exams, even if screening intervals are longer.

Complications

If left untreated or if treatment complications arise, the following issues may develop:

• Local invasion – Extension into the bladder, ureters, or rectum causing hematuria, urinary obstruction, or severe constipation.
• Persistent or heavy vaginal bleeding – Can lead to anemia, fatigue, and the need for transfusions.
• Fistula formation – Abnormal connections (e.g., vesicovaginal or rectovaginal fistulas) after radiation or surgery, resulting in leakage of urine or feces.
• Lymphedema – Swelling of the lower limbs following pelvic lymph node dissection or radiation.
• Secondary cancers – Slightly increased risk of bladder or vaginal cancers after radiation.
• Psychological impact – Depression, anxiety, and body‑image concerns are common and require attention.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, National Cancer Institute, American Cancer Society, FIGO Staging Guidelines, GOG‑240 Trial (JCO 2014), KEYNOTE‑158 Study (Lancet Oncol 2018), Cleveland Clinic.

```